MiR-145 is known to be associated with gemcitabine resistance in pancreatic cancer and it is believed that ErbB and VEGF signaling biological pathways were activated (Skrypek et al., 2015; Zhou et al., 2016). Here, VEGFA is linked to pancreatic neoplasm.